This glossary is here to stop common GLP-1 tablet words being used as if they mean the same thing. In this topic, one loose term can change the whole meaning of a headline. "Approved", "licensed", "available", "oral", "semaglutide", and "weight-loss tablet" are not interchangeable.
This is not just vocabulary. These terms decide whether a sentence is accurate or misleading. A page can look polished and still be wrong if it uses one of them carelessly.
| Term | Plain-English meaning | Why it matters here | Quick example |
|---|---|---|---|
| Approved / authorised | A regulator has allowed a medicine for a specific use in a specific jurisdiction. | Always name the country, route and indication. | U.S. approval does not equal UK approval. |
| Licensed in the UK | The UK regulator has authorised a product for a specified use. | A UK licence for one use does not mean every public use is allowed. | Ozempic is not a general UK weight-loss licence just because semaglutide is well known. |
| Available | A practical access question, not just a regulatory one. | A medicine can exist and still be hard to access, limited, or not relevant to the route being discussed. | Rybelsus exists, but that is not the same as a broad oral UK weight-loss market. |
| Indication | The medical use a medicine is authorised or studied for. | Diabetes and weight management are not interchangeable. | Rybelsus and Wegovy both involve semaglutide but sit in different use contexts. |
| Route | How the medicine is taken: tablet, injection or another form. | Different routes can have different labels, routines and reader expectations. | "Wegovy" does not automatically tell you whether the current answer is a tablet or injection. |
| Molecule | The active substance, such as semaglutide or orforglipron. | Brand names can hide the fact that two products are not the same medicine. | Foundayo is orforglipron, not semaglutide. |
| Brand | The marketed product name, such as Rybelsus, Wegovy, Ozempic or Foundayo. | Brand familiarity often outruns factual route and status knowledge. | "Ozempic pill" is often a search phrase, not a clean UK product answer. |
| Endpoint | The main outcome a trial is designed to measure. | You need to know whether a trial measured weight, HbA1c, cardiovascular outcomes, or something else. | A strong HbA1c result does not automatically answer a weight-management question. |
| Comparator | What the medicine was compared with in a study. | Placebo comparisons and active-treatment comparisons tell you different things. | "Beat placebo" and "beat another medicine" are not the same claim. |
| Real-world evidence | Evidence from routine care rather than a tightly controlled trial. | Useful for practice context, but not a replacement for regulator status. | Real-world UK Rybelsus data helps with context, not licensing language. |
| Pipeline | A medicine or route that is being developed, studied, or launched elsewhere but is not yet the settled local answer. | Pipeline material should never be written as if it is already current UK reality. | Foundayo matters, but it is still not the current UK oral anchor. |
| Prescription-only | A medicine requires appropriate clinical assessment and a legal prescription. | Online visibility is not proof of safe or lawful access. | A social media seller is not evidence of legitimate UK availability. |